Fig. 2

Survival analysis of OS by IL2RA mRNA expression levels in AML cohorts. a In our AML clinical cohort, the OS of patients with higher IL2RA expression are significantly shorter than those with lower expression levels (p < 0.001), with the median OS 20.3 months vs. 66.9 months. b In CBF AML, the OS of patients with higher IL2RA expression are significantly shorter than those with lower expression levels (p = 0.002), with the median OS 25.0 months vs. 71.8 months. c In intermediate-risk AML, the OS of patients with higher IL2RA expression are significantly shorter than those with lower expression levels (p < 0.001), with the median OS 17.3 months vs. 66.9 months. d In 80 TCGA intermediate-risk AML cases, higher IL2RA expression showed significantly shorter OS (p < 0.001), with the median OS 7.5 months vs. 22.3 months